Evidence map›Paper›PMID 39941719›Full record

ArticleCancers2025

Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0.

Fernando Solano, Ignacio Criado, Nahir Moreno, Carlos Gomez-Gonzalez, Ana Lerma-Verdejo, Cristina Teodosio, María Dolores Martinez-Moya, Iryna Luts, Teresa Contreras, Guillermo Oliva-Ariza and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fernando SolanoHematology Service, Hospital General Universitario Nuestra Señora del Prado, 45600 Talavera de la Reina, Spain.
Ignacio CriadoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), 37007 Salamanca, Spain.
Nahir MorenoHematology Service, Hospital General Universitario Nuestra Señora del Prado, 45600 Talavera de la Reina, Spain.
Carlos Gomez-GonzalezHematology Service, Hospital General Universitario Nuestra Señora del Prado, 45600 Talavera de la Reina, Spain.
Ana Lerma-VerdejoHematology Service, Hospital General Universitario Nuestra Señora del Prado, 45600 Talavera de la Reina, Spain.
Cristina TeodosioTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), 37007 Salamanca, Spain.ORCID 0000-0002-2097-7199
María Dolores Martinez-MoyaHematology Service, Hospital General Universitario Nuestra Señora del Prado, 45600 Talavera de la Reina, Spain.
Iryna LutsHematology Service, Hospital General Universitario Nuestra Señora del Prado, 45600 Talavera de la Reina, Spain.
Teresa ContrerasBiochemistry Service, University Hospital of Salamanca, 37007 Salamanca, Spain.
Guillermo Oliva-ArizaTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), 37007 Salamanca, Spain.ORCID 0000-0002-9653-9849
Blanca Fuentes HerreroTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), 37007 Salamanca, Spain.
Jose Manuel Serrano-LozanoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), 37007 Salamanca, Spain.
Julia AlmeidaTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), 37007 Salamanca, Spain.ORCID 0000-0003-3124-8917
Alberto OrfaoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-University of Salamanca), 37007 Salamanca, Spain.ORCID 0000-0002-0007-7230

Funding

Cancer Research UK Early Cancer Research Initiative Network on MBL (ECRINM3) ACCELERATOR awardCentro de Investigación Biomédica en Red de Cáncer CB16/12/00400European Union 0639-IDIAL-NET-3-3 (INTERREG POCTEP Spain-Portugal)European Union USAL4EXCELLENCE fellowship No. 101034371Instituto de Salud Carlos III PI22/00674Ministerio de Ciencia, Innovación y Universidades IJC2020-044160-I
6 · The paper itself

Abstract

BACKGROUND/

objectivesDespite the current international prognostic index for chronic lymphocytic leukemia (CLL) being widely accepted and broadly used, it does not consider the kinetics of the B-cell clone over time. Here, we investigated the potential association between distinct features of leukemic cells and other immune cells in blood and the kinetics of clonal B-cells in CLL stage Binet A/Rai 0 (A/0) patients; Methods: Based on the leukemia cell kinetics, 69 CLL A/0 cases followed for a median of 105 months were classified as carrying stable (

Indexed as

chronic lymphocytic leukemiaflow cytometryimmunitylymphocyte doubling timetime to first therapy

Identifiers

PMID39941719
PMCPMC11815973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.